Suppr超能文献

FLT3-ITD 敲入会损害造血干细胞静止/平衡,导致骨髓增生性肿瘤。

FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.

机构信息

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

出版信息

Cell Stem Cell. 2012 Sep 7;11(3):346-58. doi: 10.1016/j.stem.2012.05.027.

Abstract

Internal tandem duplication (ITD) mutations within the FMS-like tyrosine kinase-3 (FLT3) render the receptor constitutively active driving proliferation and survival in leukemic blasts. Expression of FLT3-ITD from the endogenous promoter in a murine knockin model results in progenitor expansion and a myeloproliferative neoplasm. In this study, we show that this expansion begins with overproliferation within a compartment of normally quiescent long-term hematopoietic stem cells (LT-HSCs), which become rapidly depleted. This depletion is reversible upon treatment with the small molecule inhibitor Sorafenib, which also ablates the disease. Although the normal LT-HSC has been defined as FLT3(-) by flow cytometric detection, we demonstrate that FLT3 is capable of playing a role within this compartment by examining the effects of constitutively activated FLT3-ITD. This indicates an important link between stem cell quiescence/homeostasis and myeloproliferative disease while also giving novel insight into the emergence of FLT3-ITD mutations in the evolution of leukemic transformation.

摘要

内部串联重复(ITD)突变在 FMS 样酪氨酸激酶-3(FLT3)内使受体持续激活,驱动白血病母细胞的增殖和存活。在鼠基因敲入模型中,内源性启动子表达的 FLT3-ITD 导致祖细胞扩增和骨髓增生性肿瘤。在这项研究中,我们表明这种扩增始于正常静止的长期造血干细胞(LT-HSC)中一个过度增殖的隔室,该隔室迅速耗竭。用小分子抑制剂索拉非尼治疗可逆转这种耗竭,同时也能消除疾病。尽管正常的 LT-HSC 通过流式细胞术检测被定义为 FLT3(-),但我们通过检查组成性激活的 FLT3-ITD 的作用,证明 FLT3 能够在这个隔室内发挥作用。这表明干细胞静止/平衡与骨髓增生性疾病之间存在重要联系,同时也为白血病转化过程中 FLT3-ITD 突变的出现提供了新的见解。

相似文献

3
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Oncotarget. 2017 Feb 14;8(7):10931-10944. doi: 10.18632/oncotarget.14539.
4
NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Leukemia. 2015 Jul;29(7):1470-7. doi: 10.1038/leu.2015.95. Epub 2015 Apr 14.
5
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.
6
Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.
J Exp Med. 2017 Jul 3;214(7):2005-2021. doi: 10.1084/jem.20161418. Epub 2017 Jun 21.
7
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
Blood. 2016 Jun 9;127(23):2867-78. doi: 10.1182/blood-2015-05-646786. Epub 2016 Apr 21.
8
Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
Cancer Lett. 2016 Jul 28;377(2):149-57. doi: 10.1016/j.canlet.2016.04.040. Epub 2016 Apr 28.
10
Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.
Blood. 2008 Apr 1;111(7):3849-58. doi: 10.1182/blood-2007-08-109942. Epub 2008 Feb 1.

引用本文的文献

2
Targeting leukemic stem cell dormancy in --driven acute myeloid leukemia.
Haematologica. 2025 Sep 1;110(9):1900-1902. doi: 10.3324/haematol.2025.287644. Epub 2025 May 8.
4
In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy.
Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. doi: 10.1016/j.ccell.2024.10.009.
5
Leukemic stem cells and therapy resistance in acute myeloid leukemia.
Haematologica. 2023 Feb 1;108(2):353-366. doi: 10.3324/haematol.2022.280800.
7
Molecular regulation of hematopoietic stem cell quiescence.
Cell Mol Life Sci. 2022 Mar 31;79(4):218. doi: 10.1007/s00018-022-04200-w.
8
Inflammasome Activation in Myeloid Malignancies-Friend or Foe?
Front Cell Dev Biol. 2022 Jan 27;9:825611. doi: 10.3389/fcell.2021.825611. eCollection 2021.
9
TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity.
Cell Stem Cell. 2022 Feb 3;29(2):298-314.e9. doi: 10.1016/j.stem.2021.12.007. Epub 2022 Jan 18.
10
Fms-like tyrosine kinase 3 is a regulator of the cardiac side population in mice.
Life Sci Alliance. 2021 Dec 13;5(3). doi: 10.26508/lsa.202101112. Print 2022 Mar.

本文引用的文献

1
Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.
Blood. 2012 Mar 22;119(12):2883-94. doi: 10.1182/blood-2011-10-382283. Epub 2012 Feb 8.
2
All hematopoietic cells develop from hematopoietic stem cells through Flk2/Flt3-positive progenitor cells.
Cell Stem Cell. 2011 Jul 8;9(1):64-73. doi: 10.1016/j.stem.2011.04.021.
3
FLT3 expression initiates in fully multipotent mouse hematopoietic progenitor cells.
Blood. 2011 Aug 11;118(6):1544-8. doi: 10.1182/blood-2010-10-316232. Epub 2011 May 31.
4
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Blood. 2011 Mar 24;117(12):3294-301. doi: 10.1182/blood-2010-08-301796. Epub 2011 Jan 26.
5
Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice.
Blood. 2011 Mar 17;117(11):3131-9. doi: 10.1182/blood-2010-05-286070. Epub 2011 Jan 12.
6
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
J Clin Oncol. 2010 Apr 10;28(11):1856-62. doi: 10.1200/JCO.2009.25.4888. Epub 2010 Mar 8.
8
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
Leuk Res. 2010 Jun;34(6):752-6. doi: 10.1016/j.leukres.2009.10.001. Epub 2009 Oct 29.
9
Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.
Mol Cell. 2009 Oct 23;36(2):326-39. doi: 10.1016/j.molcel.2009.09.019.
10
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
Blood. 2009 Dec 3;114(24):5034-43. doi: 10.1182/blood-2008-12-196055. Epub 2009 Oct 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验